Systemic Juvenile Idiopathic Arthritis
Conditions
Keywords
SJIA, Systemic Juvenile Idiopathic Arthritis, children, systemic autoinflammatory disease, ACZ885, canakinumab, human monoclonal anti-interleukin-1β (IL-1 β) antibody, hildhood immunizations vaccinations
Brief summary
This two-part open-label, multi-arm, non-comparative study will collect long-term safety, efficacy and tolerability data from patients who were responsive to canakinumab from study CACZ885G2301E1 (Cohort 1), and from patients who are treatment naïve to canakinumab (Cohort 2). In addition, the effect of inactivated vaccines in an SJIA patient population will be assessed for the development of adequate (protective) antibody levels following immunization according to respective local vaccination guidelines. Study Part I: All patients will be treated with canakinumab 4 mg/kg every 4 weeks (or 2 mg/kg every 4 weeks for Cohort 1 patients who are receiving that dose in CACZ885G2301E1) until study end unless discontinuation occurs, or until they qualify for Part II of the study. Study Part II: Patients who are eligible will be randomized to receive canakinumab at a reduced dose or prolonged dose interval (see requirements for dose reduction/dose interval prolongation below). Patients in Cohort 1 receiving 2 mg/kg q4wk in CACZ885G2301E1 will not be randomized but will be part of the treatment arm canakinumab dose reduction if they are eligible.
Interventions
DRUGACZ885
DRUGCanakinumab
Sponsors
PRINTO / PRCSG
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 20 Years
Healthy volunteers
No
Inclusion criteria
Key inclusion criteria: Cohort 1: 1\. All patients currently enrolled in study CACZ885G2301E1, including patients who discontinued canakinumab therapy for inactive disease in CACZ885G2301E1 as per physician discretion and who are now currently in a flare and require canakinumab therapy again Cohort 2: 1. Male and female patients aged ≥ 2 to \< 20 years at the time of the screening visit 2. Confirmed diagnosis of SJIA as per ILAR definition that must have occurred at least 2 months prior to enrollment with an onset of disease \< 16 years of age: • Arthritis in one or more joints, with or preceded by fever of at least 2 weeks duration that is documented to be daily/quotidian for at least 3 days and accompanied by one or more of the following: * Evanescent non-fixed erythematous rash, * Generalized lymph node enlargement, * Hepatomegaly and/ or splenomegaly, * Serositis 3. Active systemic disease at the time of baseline visit defined as having 2 or more of the following: * Documented spiking, intermittent fever (body temperature \> 38°C) for at least 1 day during the screening period and within 1 week before first canakinumab dose, * At least 2 joints with active arthritis (using ACR definition of active joint), * C-reactive protein (CRP) \> 30 mg/L (normal range \< 10 mg/L), * Rash, * Serositis, * Lymphadenopathy, * Hepatosplenomegaly 4. Patient's willingness to discontinue anakinra, rilonacept, tocilizumab or other experimental drug under close monitoring 5. Patients who are scheduled to receive an immunization, according to their local vaccination guidelines, with an inactivated vaccine and willing to participate in the assessment schedule for vaccinated patients Key
Exclusion criteria
Cohort 1 and Cohort 2: 1. Active or recurrent bacterial, fungal or viral infection at the time of enrollment 2. Underlying metabolic, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and/ or places the patient at unacceptable risk for participation in an immunomodulatory therapy. 3. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 4. Live vaccinations within 3 months prior to the start of the study. Cohort 2: The following additional key
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long-term safety and tolerability of canakinumab and the retention rate of canakinumab-treated patients | Days 1 to 533 | Outcome Measure Description: The long-term safety and tolerability of canakinumab and the retention rate of canakinumab-treated patients will be evaluated by monitoring of serious adverse events and adverse events leading to discontinuation of study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients who meet the adapted pediatric ACR, its individual components, and the Juvenile Arthritis Disease Activity Score [JADAS] over time | Days 1 to 533 | Outcome Measure Description: Patients will be classified into the adapted pediatric ACR categories to characterize their magnitude of efficacy response. JADAS will be derived from physician global assessment, parent/patient global assessment, active joint count and CRP. |
| The level of systemic corticosteroid tapering achieved in Part I | Day 1 to start of Part II | Patients will be classified into the following 3 categories: ≥ 0.2 mg/kg at end of Part I, those who reach a corticosteroid dose between \>0-\<0.2 mg/kg and those who reach corticosteroid free regimen. |
| The level of canakinumab tapering achieved after randomization to the dose reduction arm or dose interval prolongation treatment arm in Part II | from start of Part II to Day 533 | In the canakinumab dose reduction arm, patients will be classified into the following 3 categories: Number of patients who are able to reach 1mg/kg q4wk at the end of Part II, canakinumab free regimen by the end of Part II and those who come back to 2mg/kg q4wk at the end of Part II. In the canakinumab dose interval arm, patients will be classified into the following 3 categories: Number of patients who are able to reach 4mg/kg q12wk at the end of Part II, canakinumab-free regimen by the end of Part II and those who come back to 4mg/kg q8wk at the end of Part II. |
| The time to treatment failure in Part II | from start of Part II to Day 533 | Time to treatment failure (TTF) is defined as time from randomization to the date when the patient's worsened SJIA disease activity requires increasing the doze or shortening the treatment interval of canakinumab or the date the patient is withdrawn from the study due to a safety concern. |
Outcome results
None listed